Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise

2024-03-20

细胞疗法免疫疗法

Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring its first prospect into clinical testing.

The high-profile startup, formed by a group of pioneering cell therapy and messenger RNA researchers, secured the financing from a wide range of investors led by RA Capital and including five pharmaceutical companies, it said Wednesday. Johnson & Johnson is one of Capstan’s new backers, joining existing investors Pfizer, Bristol Myers Squibb, Eli Lilly and Bayer, among others. The startup has now raised $340 million since 2021.

Capstan will use the funds to advance its work developing cell therapies designed to be administered through a single infusion, rather than via a laborious process that involves genetically manipulating cells in a lab. If successful, these “in vivo” cell therapies could help broaden the reach of so-called CAR-T therapy, and be more convenient and accessible to patients.

The startup is one of a handful of young drugmakers to emerge in the last three years to pursue in vivo cell therapy research and attract funding. Multiple pharmaceutical companies have shown interest, investing in Capstan as well as others like Asgard Therapeutics and Ensoma. Another well-funded in vivo cell therapy startup, Umoja Biopharma, signed a collaboration deal with AbbVie in January.

Capstan’s goal is to use messenger RNA technology to coax the body into making its own CAR-T cells. Early research published in Science and Nature showed the feasibility of the approach in animals, but it’s nonetheless a daunting task that’s never been attempted in humans.

“Our immune system is primed to attack anything that’s delivering RNA. So the main challenge is, how do you make it stealth and get it into cells without causing a lot of immune activation?” said CAR-T innovator and University of Pennsylvania scientist Carl June, one of Capstan’s co-founders, in an interview with BioPharma Dive in 2022.

Since then, the company has progressed to the point that it now has a lead program. Called CPTX2309, it is being developed for autoimmune diseases and delivers an mRNA payload that redirects T cells to cells with the protein CD19.

That particular protein is found on the antibody-making B cells that malfunction in a variety of autoimmune diseases. It’s also the target of a number of cell therapies in clinical testing for lupus and other inflammatory conditions, all of which aim to induce a “reset” of a patient’s disease. Many of those programs involve “ex vivo” approaches, however.

Capstan said the funds will get its lead program to early proof-of-concept studies and help advance the rest of its pipeline.

“We are grateful for the support of both new and existing investors as we enter a critical phase of execution, with the ultimate goal of bringing new therapeutic modalities to patients,” said CEO Laura Shawver, in a statement.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构